Targeting HER2 in NSCLC Remains Work in Progress
Corey Langer, MD, discussed the therapeutic potential for anti-HER2 agents in non–small cell lung cancer in a presentation at the 2015 International Lung Cancer Congress.
Immune Checkpoint Combination Strategies Evolving in NSCLC
A number of clinical trials are now assessing PD-1 and PD-L1 inhibitors in combination with chemotherapy, targeted therapies, and radiation therapy in an attempt to further improve outcomes for patients with non–small cell lung cancer.
Translational Advances Deliver Precision Medicine to NSCLC
Paul Bunn, MD, discussed the latest translational advances in NSCLC at the 2015 International Lung Cancer Congress.
Explosion in Next-Generation Agents on Horizon in NSCLC
Highly effective next-generation therapies are currently in development for patients with oncogene-driven non–small cell lung cancer, specifically those with alterations in EGFR, ALK, ROS1, NTRK, or a variety of other gene.
Researcher Responsible for CLL Breakthroughs Honored by ASH
John C. Byrd, MD, discusses receiving the American Society of Hematology’s 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.
Neoadjuvant Pertuzumab Regimen Approved in Europe for HER2-Positive Early Breast Cancer
The European Commission has approved the combination of pertuzumab, trastuzumab, and chemotherapy as a neoadjuvant therapy for adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer who are at high risk of recurrence.
Regulatory Approval Sought for Eribulin in Soft Tissue Sarcoma
An application has been submitted to the FDA for eribulin mesylate (Halaven) as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.